Email updates

Keep up to date with the latest news and content from Genome Biology and BioMed Central.

Research news

Blocking myostatin

Jonathan B Weitzman

Author Affiliations

Genome Biology 2002, 3:spotlight-20021203-01  doi:10.1186/gb-spotlight-20021203-01


The electronic version of this article is the complete one and can be found online at:


Published:3 December 2002

© 2002 BioMed Central Ltd

Research news

Myostatin is a member of the TGF-β family of signaling molecules that appears to act as a negative regulator of skeletal muscle growth. In the November 28 Nature Bogdanovitch et al. demonstrate that inhibition of myostatin could be used as a therapeutic approach to increase muscle mass and treat myopathy diseases (Nature 2002, 420:418-421). Antibodies against myostatin were tested in the mdx mouse model of Duchenne muscular dystrophy (DMD). The treated mice gained weight and displayed increased muscle mass and caloric output. The treatment caused a functional improvement of the dystrophic phenotype, suggesting that similar pharmacological strategies targeting myostatin might be applied to treat human muscular diseases and offer an alternative to gene therapy.

References

  1. Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member.

    PubMed Abstract OpenURL

  2. [http://www.nature.com] webcite

    Nature